What question did this study set out to answer?

To compare clinical outcomes of FTD-TPI combined with bevacizumab versus FTD-TPI or regorafenib in metastatic colorectal cancer.

March 30, 2026Open Access

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

Key Points

To compare clinical outcomes of FTD-TPI combined with bevacizumab versus FTD-TPI or regorafenib in metastatic colorectal cancer.
Analyzed a large multicenter cohort of mCRC patients.
Compared progression-free survival (PFS) and disease control rate (DCR) among treatment groups.
Examined molecular subgroup responses, particularly KRAS mutations.
FTD-TPI plus bevacizumab showed improved PFS compared to FTD-TPI alone.
DCR was significantly higher with FTD-TPI plus bevacizumab than with regorafenib.
Benefits were consistent across various molecular subgroups, including those with KRAS mutations.

Abstract

In this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRASG12 mutations.

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

Key Points

Abstract

Cite This Study